Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...

An emergency doctor has highlighted three “worrying” symptoms that could indicate a deadly cancer that kills around 12,000 ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

In the next in our series, GP Dr Roger Henderson debunks common myths about prostate cancer – and highlights some less ...